ATRIAL FIBRILLATION MARKET ANALYSIS

Atrial Fibrillation Market, By Type (Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation, and Permanent Atrial Fibrillation), By Treatment (Pharmacological Treatments (Anticoagulants, Antiarrhythmic Drugs) and Non-Pharmacological Treatments (Catheter Ablation, Surgical Procedures, Implantable Devices)), By Technology (Radiofrequency, Laser, Cryotherapy, and Others), By End User (Hospitals, Cardiac Centers, Home Care Settings, and Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

The global atrial fibrillation market is expected to witness significant growth over the forecast period driven by the rising geriatric population worldwide which is the primary demographic susceptible to atrial fibrillation. The market will further benefit from growing awareness about atrial fibrillation and availability of advanced treatment options. However, the market may face certain restraints posed by the risks and complications associated with the medical procedures involved in treatment of atrial fibrillation.
North America will continue dominating the global atrial fibrillation market backed by the presence of highly developed healthcare infrastructure and rising prevalence of cardiovascular conditions in the region. Within North America, the U.S. atrial fibrillation market holds the maximum potential owing to supportive reimbursement policies and new product approvals.
North America will emerge as the largest market globally supported by increasing healthcare expenditure and government focus on cardiac health in the region. In terms of growth rate, Asia Pacific will witness the fastest gains in the coming years attributed to huge patient pool, growing medical tourism, and improving access to healthcare in developing countries like India and China.